Zoetis Inc (NYSE:ZTS)‘s stock had its “outperform” rating reiterated by Credit Suisse Group AG in a report released on Wednesday. They presently have a $67.00 target price on the stock, up from their previous target price of $61.00. Credit Suisse Group AG’s price objective indicates a potential upside of 7.54% from the stock’s previous close.

Several other brokerages also recently issued reports on ZTS. Zacks Investment Research raised shares of Zoetis from a “sell” rating to a “hold” rating in a research report on Thursday, March 9th. Craig Hallum started coverage on shares of Zoetis in a research report on Wednesday, March 15th. They set a “buy” rating and a $65.00 price objective on the stock. Off Wall Street reissued a “strong sell” rating and set a $35.00 price objective on shares of Zoetis in a research report on Thursday, February 16th. BMO Capital Markets reissued an “outperform” rating and set a $60.00 price objective on shares of Zoetis in a research report on Sunday, February 19th. Finally, Jefferies Group LLC raised their price objective on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $58.94.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Shares of Zoetis (NYSE:ZTS) traded up 1.42% during midday trading on Wednesday, hitting $62.30. 3,869,148 shares of the stock were exchanged. The company has a market cap of $30.58 billion, a PE ratio of 36.22 and a beta of 1.07. Zoetis has a 12 month low of $45.28 and a 12 month high of $62.49. The stock has a 50 day moving average price of $56.75 and a 200-day moving average price of $53.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 4th. The company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.05. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The firm had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period last year, the business earned $0.48 EPS. Zoetis’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, analysts predict that Zoetis will post $2.34 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Thursday, June 15th will be given a dividend of $0.105 per share. This represents a $0.42 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Tuesday, June 13th. Zoetis’s payout ratio is currently 30.44%.

TRADEMARK VIOLATION NOTICE: “Credit Suisse Group AG Reiterates Outperform Rating for Zoetis Inc (ZTS)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/24/credit-suisse-group-ag-reiterates-outperform-rating-for-zoetis-inc-zts.html.

In other Zoetis news, insider Catherine A. Knupp sold 5,785 shares of Zoetis stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $60.16, for a total transaction of $348,025.60. Following the completion of the transaction, the insider now owns 24,415 shares in the company, valued at $1,468,806.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock worth $1,925,722,000 after buying an additional 34,679,064 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Zoetis by 12.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 34,863,382 shares of the company’s stock worth $1,813,244,000 after buying an additional 3,806,515 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Zoetis by 1.7% in the first quarter. Vanguard Group Inc. now owns 32,744,421 shares of the company’s stock worth $1,747,570,000 after buying an additional 546,287 shares during the last quarter. State Street Corp boosted its position in shares of Zoetis by 4.9% in the first quarter. State Street Corp now owns 21,256,557 shares of the company’s stock worth $1,134,453,000 after buying an additional 986,680 shares during the last quarter. Finally, Morgan Stanley boosted its position in shares of Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock worth $780,119,000 after buying an additional 9,442,207 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

12 Month Chart for NYSE:ZTS

Receive News & Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.